Abeona Therapeutics Inc. Sustainability Profile
Abeona Therapeutics Inc., a pioneering biopharmaceutical company headquartered in the United States, focuses on developing innovative gene and cell therapies for rare genetic diseases. Founded in 2013, Abeona has made significant strides in the industry, particularly in the fields of gene therapy and regenerative medicine, with a commitment to addressing unmet medical needs. The company’s core products include its proprietary AAV-based gene therapies, which are designed to treat conditions such as Sanfilippo syndrome and other lysosomal storage disorders. Abeona's unique approach leverages advanced technologies to deliver targeted treatments, setting it apart in a competitive market. With a strong pipeline and strategic partnerships, Abeona Therapeutics is well-positioned as a leader in the gene therapy landscape, continually striving to improve patient outcomes and advance the field of genetic medicine.
DitchCarbon Score
How does Abeona Therapeutics Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Abeona Therapeutics Inc.'s score of 25 is lower than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Abeona Therapeutics Inc.'s reported carbon emissions
Abeona Therapeutics Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As of now, Abeona Therapeutics Inc. does not inherit emissions data from any parent or related organisations, meaning all information is self-reported and reflects their current status in climate commitments. Without specific emissions data or reduction initiatives, it is unclear how the company is addressing its carbon footprint or contributing to climate action within the biopharmaceutical industry. In the absence of concrete data, it is essential for Abeona Therapeutics Inc. to establish clear climate commitments and reduction targets to align with industry standards and expectations for sustainability.
How Carbon Intensive is Abeona Therapeutics Inc.'s Industry?
How Carbon Intensive is Abeona Therapeutics Inc.'s Location?
Abeona Therapeutics Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Abeona Therapeutics Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
